Wells Fargo
CVKD icon

Wells Fargo’s Cadrenal Therapeutics CVKD Stock Holding History

Wells Fargo’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$331 Hold
99
– – ﹤0.01% 6553
2026
Q1 		$507 Hold
99
– – ﹤0.01% 6396
2025
Q4 		$671 Hold
99
– – ﹤0.01% 6313
2025
Q3 		$1.37K Sell
99
-1
-1% -$12 ﹤0.01% 6233
2025
Q2 		$1.21K Hold
100
– – ﹤0.01% 6287
2025
Q1 		$1.76K Buy
+100
New +$1.84K ﹤0.01% 6176
2024
Q2 		– Sell
-4
Closed -$33 – 7018
2024
Q1 		$33 Hold
4
– – ﹤0.01% 6956
2023
Q4 		$39 Buy
4
+1
+33% +$8 ﹤0.01% 6988
2023
Q3 		$34 Buy
3
+2
+200% +$28 ﹤0.01% 7023
2023
Q2 		$15 Hold
1
– – ﹤0.01% 7363
2023
Q1 		$14 Buy
+1
New +$30 ﹤0.01% 7444

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Wells Fargo's CVKD Position: Q2 2026 in Review

Wells Fargo held its Cadrenal Therapeutics (CVKD) position steady in Q2 2026 at 99 shares worth $331. The position accounts for ﹤0.01% of the portfolio, ranked #6553.

Wells Fargo first reported a position in CVKD in Q1 2023 and has held it in 11 quarters since. The position peaked at $1.76K in Q1 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

  • Wells Fargo held 99 shares of Cadrenal Therapeutics worth $331 as of Q2 2026.
  • Wells Fargo left its Cadrenal Therapeutics share count unchanged in Q2 2026.
  • Cadrenal Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6553 holding.
  • Wells Fargo first reported a position in Cadrenal Therapeutics in Q1 2023 and has held it in 11 quarters since.
  • Wells Fargo's Cadrenal Therapeutics position peaked at $1.76K in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.